HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2

Microbes and Infection

Volumn 7, Issue 15, 2005, Pages 1492-1500

  Mori, Isamu ^a,b,c   Liu, Beixing ^c   Goshima, Fumi ^b   Ito, Hiroyasu ^a   Koide, Naoki ^a   Yoshida, Tomoaki ^a   Yokochi, Takashi ^a   Kimura, Yoshinobu ^c   Nishiyama, Yukihiro ^b  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

Author keywords

Herpes simplex virus; HF10; Live attenuated vaccine; Neuroinvasiveness

Indexed keywords

LIVE VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLONE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; MOUSE; NONHUMAN; OLFACTORY CORTEX; PHENOTYPE; PRIORITY JOURNAL; TRIGEMINUS GANGLION; VACCINATION; VIRUS ATTENUATION; VIRUS GENE; VIRUS STRAIN; VIRUS VIRULENCE; VOMERONASAL ORGAN;

ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; MICE; MICE, INBRED C57BL; NEURONS; OLFACTORY NERVE; TRIGEMINAL NERVE; VACCINES, ATTENUATED; VOMERONASAL ORGAN;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 28944445461     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2005.05.007     Document Type: Article

References (31)

1. I. Mori, Y. Nishiyama, T. Yokochi, and Y. Kimura Olfactory transmission of neurotropic viruses J. Neurovirol. 11 2005 129 137
2. Y. Nishiyama, H. Kimura, and T. Daikoku Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2 J. Virol. 65 1991 4520 4524
3. I. Mori, F. Goshima, H. Ito, N. Koide, T. Yoshida, T. Yokochi, Y. Kimura, and Y. Nishiyama The vomeronasal chemosensory system as a route of neuroinvasion by herpes simplex virus Virology 334 2005 51 58
4. I. Mori, B. Liu, M.J. Hossain, H. Takakuwa, T. Daikoku, Y. Nishiyama, H. Naiki, K. Matsumoto, T. Yokochi, and Y. Kimura Successful protection by amantadine hydrochloride against lethal encephalitis caused by a highly neurovirulent recombinant influenza A virus Virology 303 2002 287 296
5. I. Mori, Y. Kimura, H. Naiki, R. Matsubara, T. Takeuchi, T. Yokochi, and Y. Nishiyama Reactivation of HSV-1 in the brain of patients with familial Alzheimer's disease J. Med. Virol. 73 2004 605 611
6. F. Rapp, and Y. Nishiyama Inhibition of herpes simplex virus type 2-induced biochemical transformation by interferon J. Virol. 33 1980 543 546
7. P.G.E. Kennedy, and A. Chaudhuri Herpes simplex encephalitis J. Neurol. Neurosurg. Psychiatry 73 2002 237 238
8. L.R. Stanberry Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines Herpes 11 2004 161A 169A
9. Y. Becker, J. Hadar, E. Tabor, T. Ben-Hur, I. Raibstein, A. Rosen, and G. Darai A sequence in HpaI-P fragment of herpes simplex virus-1 DNA determines intraperitoneal virulence in mice Virology 149 1986 255 259
10. A. Rösen-Wolff, W. Lamade, C. Berkowitz, Y. Becker, and G. Darai Elimination of UL56 gene by insertion of LacZ cassette between nucleotide position 116030 and 121753 of the herpes simplex virus type 1 genome abrogates intraperitoneal pathogenicity in tree shrews and mice Virus Res. 20 1991 205 221
11. C. Berkowitz, M. Moyal, A. Rösen-Wolff, G. Darai, and Y. Becker Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice Arch. Virol. 134 1994 73 83
12. R. Kehm, A. Rösen-Wolff, and G. Darai Restitution of the UL56 gene expression of HSV-1 HFEM led to restoration of virulent phenotype; deletion of the amino acids 217-234 of the UL56 protein abrogates the virulent phenotype Virus Res. 40 1996 17 31
13. T. Koshizuka, Y. Kawaguchi, and Y. Nishiyama Herpes simplex virus type 2 membrane protein UL56 associates with the kinesin motor protein KIF1A J. Gen. Virol. 86 2005 527 533
14. J. Zhu, W. Kang, M.E. Marquart, J.M. Hill, X. Zheng, T.M. Block, and N.W. Fraser Identification of a novel 0.7:kb polyadenylated transcript in the LAT promoter region of HSV-1 that is strain specific and may contribute to virulence Virology 265 1999 296 307
15. J. Naito, R. Mukerjee, K.R. Mott, W. Kang, N. Osorio, N.W. Fraser, and G.-C. Perng Identification of a protein encoded in the herpes simplex virus type 1 latency associated transcript promoter region Virus Res. 108 2005 101 110
16. H. Yamada, Y.-M. Jiang, S.-I. Oshima, T. Daikoku, Y. Yamashita, T. Tsurumi, and Y. Nishiyama Characterization of the UL55 gene product of herpes simplex virus type 2 J. Gen. Virol. 79 1998 1989 1995
17. S.A. Yuhasz, and J.G. Stevens Glycoprotein B is a specific determinant of herpes simplex virus type 1 neuroinvasiveness J. Virol. 67 1993 5948 5954
18. J.G. Stevens HSV-1 neuroinvasiveness Intervirology 35 1993 152 163
19. C. Van Sant, Y. Kawaguchi, and B. Roizman A single amino acid substitution in the cyclin D binding domain of the infected cell protein no. 0 abrogates the neuroinvasiveness of herpes simplex virus without affecting its ability to replicate Proc. Natl. Acad. Sci. USA 96 1999 8184 8189
20. J.R. Simms, A.W. Heath, and R. Jennings Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs J. Infect. Dis. 181 2000 1240 1248
21. J.R. Simms, R. Jennings, V.J. Richardson, and A.W. Heath Large-scale comparison of experimental adjuvants with herpes simplex virus vaccine reveals a correlation of protection with IgG2a and IgG2b responses J. Med. Virol. 68 2002 82 91
22. C.R. Rinaldo Jr., and D.J. Torpey 3rd Cell-mediated immunity and immunosuppression in herpes simplex virus infection Immunodeficiency 5 1993 33 90
23. J.E. Blaney Jr., E. Nobusawa, M.A. Brehm, R.H. Bonneau, L.M. Mylin, T.-M. Fu, Y. Kawaoka, and S.S. Tevethia Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity J. Virol. 72 1998 9567 9574
24. M. Ashkenazi, and S. Kohl Reduced antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells of salivary polymorphonuclear leukocytes and inhibition of peripheral blood polymorphonuclear leukocyte cytotoxicity by saliva J. Immunol. 144 1990 4781 4787
25. A. Casadevall, and L.-A. Pirofski Antibody-mediated regulation of cellular immunity and the inflammatory response Trends Immunol. 24 2003 474 478
26. N. Goel, Q. Rong, D. Zimmerman, and K.S. Rosenthal A L.E.A.P.S.™ heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection Vaccine 21 2003 4410 4420
27. D. Kirn, R.L. Martuza, and J. Zwiebel Replication-selective virotherapy for cancer: biological principles, risk management and future directions Nat. Med. 7 2001 781 787
28. H. Takakuwa, F. Goshima, N. Nozawa, T. Yoshikawa, H. Kimata, A. Nakao, A. Nawa, T. Kurata, T. Sata, and Y. Nishiyama Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice Arch. Virol. 148 2003 813 825
29. H. Kimata, H. Takakuwa, F. Goshima, O. Teshigahara, A. Nakao, T. Kurata, T. Sata, and Y. Nishiyama Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses Hepatogastroenterology 50 2003 961 966
30. O. Teshigahara, F. Goshima, K. Takao, S. Kohno, H. Kimata, A. Nakao, and Y. Nishiyama Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF10 J. Surg. Oncol. 85 2004 42 47
31. A. Nakao, H. Kimata, T. Imai, T. Kikumori, O. Teshigahara, T. Nagasaka, F. Goshima, and Y. Nishiyama Intratumoral injection of herpes simpex virus HF10 in recurrent breast cancer Ann. Oncol. 15 2004 988 989